NVIDIA's BioNeMo Becomes Pharma's AI Backbone as Novo Nordisk Offloads Parkinson's Risk to AI Partner
NVIDIA's BioNeMo platform is emerging as the default AI infrastructure for pharmaceutical R&D, with Eli Lilly and Thermo Fisher signing co-innovation lab agreements. Novo Nordisk's stock climbed 24.9% monthly as it licensed its Parkinson's cell therapy to AI-native partner Cellular Intelligence and shuttered its internal unit. FDA Fast Track designation for the program signals regulatory pathways are clearing for AI-driven drug development.
Salvado•